Autologous Cytokine-Induced Killer Cell Immunotherapy for Patients with High-Risk Diffuse Large B Cell Lymphoma After the First Complete Remission.

Min ZhouJing WangCui-Ping LiJing-Yan XuBing Chen

Published in: OncoTargets and therapy (2020)

Autologous CIK cell immunotherapy has emerged as a safe and efficacious option to improve the prognosis of patients with high-risk DLBCL after the first CR.

Keyphrases

diffuse large b cell lymphoma
cell therapy
single cell
epstein barr virus
bone marrow
stem cells
rheumatoid arthritis
high glucose
mesenchymal stem cells
diabetic rats
platelet rich plasma
systemic lupus erythematosus
disease activity
stress induced